APEIRON Biologics
Apeiron Biologics is developing a potential drug candidate APN01, based on our proprietary ACE2 platform to address the growing global health threat.
Rankings by
Национальный рейтинг6th
in Austria Региональный рейтинг363rd
in Western Europe Глобальный рейтинг1614th
worldwide